Cerus Corp (CERS) Share Price

Mick--in again on 12/2 at 30,000 shares. You in Cers?I'm doing a Short term trade only. Looked like a little Momo EOD trades.

LC

CERS

Hey Mick, Out again for a nice profit today. Are you making money here on CERS? I'm going to be buying in again (maybe) EOD.

LC

CERS

Back in EOD. Quick hitter for $900+bucks. See ya' Monday.

LC

CERS

I'm out Mick. Back in again if it goes below $1.67.

LC

CERS

hi there

It's got a gap up to file Mick, Picked up 5000 more, Don't be caught bag holding when I sell. I'll probably sell at $1.80 and buy back in on the dips.

LC

CERS

It's got a gap up to file Mick, Picked up 5000 more, Don't be caught bag holding when I sell. I'll probably sell at $1.80 and buy back in on the dips.

LC

CERS

Looks like a good buying opportunity, Big volume EOD on Friday. Mick.Short term it looks to me like it'll gap up short term. Also, quarterly results are coming 10/30. What's your opinion?

LC

CERS

https://www.stockscores.com/

I picked up 20000 shares. Let's see if we are as good at picking as we think we are. I made good returns on OKLO today too.

LC

CERS

i like cers

yes and long term hold too. writes are good.

Got my shares.

LC
CERS

Got my shares.

LC
CERS

Mick---I'm buying in Friday morning. I've done some DD on CERS and like it for a short term trade. But, of course, do your own evaluation Baaaaaa-oyz!

LC

CERS

https://www.barchart.com/stocks/quotes/CERS/overview#google_vignette

However, it's worth noting that Cerus operates with a moderate level of debt
and its liquid assets exceed short-term obligations,
potentially providing financial flexibility as it navigates regulatory challenges and pursues market expansion.

The substantial BARDA funding mentioned in the article could further strengthen the company's financial position.

Investors should also consider that Cerus is trading at a high Price / Book multiple of 6.74,
which may reflect market expectations for future growth despite current profitability challenges.

For a more comprehensive analysis, InvestingPro offers 5 additional tips for Cerus Corporation,
providing deeper insights into the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

#2 --- Cerus stock price target unchanged as TD Cowen cites evolving EU strategy and increased BARDA funding
Investing.com
Editor
Ahmed Abdulazez Abdulkadir
Company News
Published 10/17/2024, 11:02 AM

https://www.investing.com/news/company-news/cerus-stock-price-target-unchanged-as-td-cowen-cites-evolving-eu-strategy-and-increased-barda-funding-93CH-3669038

Cerus stock price target unchanged as TD Cowen cites evolving EU strategy and increased BARDA funding

On Thursday, TD Cowen maintained a positive outlook on Cerus (NASDAQ:CERS) Corporation (NASDAQ:CERS) despite a recent setback in its European regulatory progress. The firm reiterated its Buy rating and a $5.00 price target for the blood transfusion company.

Cerus recently encountered a challenge with its CE Mark application for the INTERCEPT Red Blood Cell (RBC) system in Europe,
which did not receive approval. Following this, the company is exploring alternative strategies for CE Mark submission.
Despite this hiccup in Europe, Cerus is making strides in the United States with its RBC program.
The company is planning a Pre-Market Approval (PMA) submission after the completion of its ReDeS clinical trial.

Moreover, Cerus has secured substantial support from the U.S. government,
with the Biomedical Advanced Research and Development Authority (BARDA) committing up to $248 million in additional funding.
This funding is designated to further the development of the INTERCEPT blood system,
which is designed to enhance the safety of blood transfusions by inactivating a broad range of pathogens such as viruses,
bacteria, and parasites that may be present in donated blood.

The analyst from TD Cowen highlighted these developments,
noting the company's ongoing efforts to advance its blood safety system in the U.S. market.
With the additional BARDA funding, Cerus is expected to continue its progress despite
the regulatory challenges faced in the European Union.

Investors and stakeholders in Cerus Corporation continue to watch the company's advancements
in blood safety technology and its efforts to navigate regulatory pathways in different markets.

The support from BARDA underscores the potential of the INTERCEPT blood system to address critical needs in transfusion medicine.

In other recent news, Cerus Corporation has experienced a series of significant developments.

The biomedical company's annual product revenue guidance for 2024 has been
revised upwards to between $175 million and $178 million,
marking a substantial increase from the previous range of $172 million to $175 million.
This adjustment is largely due to a 16% year-over-year growth in product revenue,
primarily driven by the increased use of Cerus' INTERCEPT blood system.

Furthermore, Cerus has secured a contract with the
Biomedical Advanced Research and Development Authority (BARDA) valued at up to $248 million.

This contract will support the development of its INTERCEPT red blood cell (RBC) system in the United States.

However, the company recently faced a setback when the European Union's review of its INTERCEPT RBC
product concluded without granting approval, citing the need for additional data.

On the analyst front, Stifel has adjusted its price target for Cerus to $3.00, down from the previous $6.00,
but maintains a Buy rating on the stock.

Meanwhile, BTIG analysts have reiterated a Neutral rating for Cerus, following the company's stronger-than-expected
performance in the second quarter.

InvestingPro Insights
While TD Cowen maintains a positive outlook on Cerus Corporation (NASDAQ:CERS),
recent InvestingPro data provides additional context for investors.

Despite the company's revenue growth of 10.79% over the last twelve months as of Q2 2023, Cerus is not currently profitable,
with an adjusted operating income of -$14.48 million for the same period.

This aligns with one of the InvestingPro Tips, which indicates that analysts do not anticipate the company will be profitable this year.

Cerus stock price target unchanged as TD Cowen cites evolving EU strategy and increased BARDA funding
Investing.com
Editor
Ahmed Abdulazez Abdulkadir
Company News
Published 10/17/2024, 11:02 AM

https://www.investing.com/news/company-news/cerus-stock-price-target-unchanged-as-td-cowen-cites-evolving-eu-strategy-and-increased-barda-funding-93CH-3669038

selling for about 2-1/2 times book value.

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT

CONCORD, CA, October 16, 2024 - Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe:



•
U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization



•
Europe – CE Mark review has concluded without approval; assessing strategy for anticipated future filing

“We are pleased with the progress we have made with our U.S. RBC program, which will now receive additional support from BARDA through a new contract valued at up to $248 million, intended to fund activities including continued improvement in the design of the product candidate and a future scale-up of commercial manufacturing activities,” commented Obi Greenman, Cerus’ president and chief executive officer. “In Europe, our CE Mark review under the Medical Device Regulation (MDR) has concluded without an approval. We believe that we can address the issues which prevented our approval in the context of an anticipated new regulatory submission.”

US – BARDA award and program update

In the U.S., Cerus has entered into a new six-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, to further advance the development of the INTERCEPT RBC system. Valued at up to $248 million, this additional funding is intended to support a planned U.S. Food and Drug Administration (FDA) modular premarket approval (PMA) application and potential post-approval studies, accelerate development of an improved version of the INTERCEPT RBC system, and scale up the chemistry, manufacturing and controls (CMC) activities to enable a broad product launch, if approved. BARDA has awarded $32.1 million for the initial base period, with additional funding contingent on meeting specific contractual milestones.

In March 2024, Cerus announced positive topline results for the BARDA-funded ReCePI study, a pivotal U.S. Phase 3 clinical trial demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients. The Company is currently enrolling patients in its ongoing, BARDA-funded RedeS clinical trial, the second pivotal U.S. Phase 3


clinical trial in patient populations requiring RBC transfusion for acute and chronic anemia. Results from both trials are expected to be part of a planned modular PMA submission to the FDA, with the planned final PMA module expected to be submitted upon the anticipated completion of the RedeS trial.

“ReCePI investigators will be presenting a number of abstracts with study data at the Annual AABB meeting next week in Houston, including a plenary presentation,” said Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer. “We have recently begun enrolling at two additional RedeS study sites, including the Turkey site, but we are still assessing the potential impact to the anticipated timing of study completion and modular PMA submission, since these new sites began enrollment later than previously anticipated.”

The new BARDA contract will be funded in whole or in part with federal funds from the Department of Health and Human Services’ Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract No. 75A50124C00046.

Europe – CE Mark review update

For Cerus’ MDR application in Europe, Cerus’ Notified Body, TÜV-SÜD, reviewed the modules for clinical, non-clinical, manufacturing and quality and found them to be satisfactory. However, the Competent Authority, CBG-MEB, reviewed the active pharmaceutical ingredient module and concluded that the data included in the module were insufficient to support the proposed classification of the impurity profile of the final product, necessitating TÜV-SÜD’s closure of Cerus’ MDR application without an approval. The Company, in collaboration with TÜV-SÜD, is assessing strategies for a potential enhanced new regulatory submission and the associated timeline.

“We continue to believe strongly in the need for pathogen inactivated RBCs and the regulatory dossier we filed in Europe. In addition to how we address the new questions CBG has raised, we want to take this opportunity to be thoughtful about leveraging the additional data that we have accumulated since our original CE Mark submission,” said Carol Moore, Cerus’ senior vice president. “For example, we believe the positive results from our U.S. Phase 3 ReCePI trial substantially expand the data available to evaluate the clinical safety and efficacy of INTERCEPT RBCs. We will be assessing how these data could allow us to propose a broader clinical indication in a potential new CE Mark submission in consultation with TÜV.”

Webcast

The Company will host a webcast later today at 5:00 P.M. EDT, during which management will provide an update on the INTERCEPT red blood cell program. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.



2


A replay will be available on Cerus’ website approximately three hours after the call through October 30, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

#2 \\// $CERS --- Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT

CONCORD, CA, October 16, 2024 - Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe:



•
U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization



•
Europe – CE Mark review has concluded without approval; assessing strategy for anticipated future filing

“We are pleased with the progress we have made with our U.S. RBC program, which will now receive additional support from BARDA through a new contract valued at up to $248 million, intended to fund activities including continued improvement in the design of the product candidate and a future scale-up of commercial manufacturing activities,” commented Obi Greenman, Cerus’ president and chief executive officer. “In Europe, our CE Mark review under the Medical Device Regulation (MDR) has concluded without an approval. We believe that we can address the issues which prevented our approval in the context of an anticipated new regulatory submission.”

US – BARDA award and program update

In the U.S., Cerus has entered into a new six-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, to further advance the development of the INTERCEPT RBC system. Valued at up to $248 million, this additional funding is intended to support a planned U.S. Food and Drug Administration (FDA) modular premarket approval (PMA) application and potential post-approval studies, accelerate development of an improved version of the INTERCEPT RBC system, and scale up the chemistry, manufacturing and controls (CMC) activities to enable a broad product launch, if approved. BARDA has awarded $32.1 million for the initial base period, with additional funding contingent on meeting specific contractual milestones.

In March 2024, Cerus announced positive topline results for the BARDA-funded ReCePI study, a pivotal U.S. Phase 3 clinical trial demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients. The Company is currently enrolling patients in its ongoing, BARDA-funded RedeS clinical trial, the second pivotal U.S. Phase 3


clinical trial in patient populations requiring RBC transfusion for acute and chronic anemia. Results from both trials are expected to be part of a planned modular PMA submission to the FDA, with the planned final PMA module expected to be submitted upon the anticipated completion of the RedeS trial.

“ReCePI investigators will be presenting a number of abstracts with study data at the Annual AABB meeting next week in Houston, including a plenary presentation,” said Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer. “We have recently begun enrolling at two additional RedeS study sites, including the Turkey site, but we are still assessing the potential impact to the anticipated timing of study completion and modular PMA submission, since these new sites began enrollment later than previously anticipated.”

The new BARDA contract will be funded in whole or in part with federal funds from the Department of Health and Human Services’ Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract No. 75A50124C00046.

Europe – CE Mark review update

For Cerus’ MDR application in Europe, Cerus’ Notified Body, TÜV-SÜD, reviewed the modules for clinical, non-clinical, manufacturing and quality and found them to be satisfactory. However, the Competent Authority, CBG-MEB, reviewed the active pharmaceutical ingredient module and concluded that the data included in the module were insufficient to support the proposed classification of the impurity profile of the final product, necessitating TÜV-SÜD’s closure of Cerus’ MDR application without an approval. The Company, in collaboration with TÜV-SÜD, is assessing strategies for a potential enhanced new regulatory submission and the associated timeline.

“We continue to believe strongly in the need for pathogen inactivated RBCs and the regulatory dossier we filed in Europe. In addition to how we address the new questions CBG has raised, we want to take this opportunity to be thoughtful about leveraging the additional data that we have accumulated since our original CE Mark submission,” said Carol Moore, Cerus’ senior vice president. “For example, we believe the positive results from our U.S. Phase 3 ReCePI trial substantially expand the data available to evaluate the clinical safety and efficacy of INTERCEPT RBCs. We will be assessing how these data could allow us to propose a broader clinical indication in a potential new CE Mark submission in consultation with TÜV.”

Webcast

The Company will host a webcast later today at 5:00 P.M. EDT, during which management will provide an update on the INTERCEPT red blood cell program. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.



2


A replay will be available on Cerus’ website approximately three hours after the call through October 30, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT

CONCORD, CA, October 16, 2024 - Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe:



•
U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization



•
Europe – CE Mark review has concluded without approval; assessing strategy for anticipated future filing

“We are pleased with the progress we have made with our U.S. RBC program, which will now receive additional support from BARDA through a new contract valued at up to $248 million, intended to fund activities including continued improvement in the design of the product candidate and a future scale-up of commercial manufacturing activities,” commented Obi Greenman, Cerus’ president and chief executive officer. “In Europe, our CE Mark review under the Medical Device Regulation (MDR) has concluded without an approval. We believe that we can address the issues which prevented our approval in the context of an anticipated new regulatory submission.”

US – BARDA award and program update

In the U.S., Cerus has entered into a new six-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, to further advance the development of the INTERCEPT RBC system. Valued at up to $248 million, this additional funding is intended to support a planned U.S. Food and Drug Administration (FDA) modular premarket approval (PMA) application and potential post-approval studies, accelerate development of an improved version of the INTERCEPT RBC system, and scale up the chemistry, manufacturing and controls (CMC) activities to enable a broad product launch, if approved. BARDA has awarded $32.1 million for the initial base period, with additional funding contingent on meeting specific contractual milestones.

In March 2024, Cerus announced positive topline results for the BARDA-funded ReCePI study, a pivotal U.S. Phase 3 clinical trial demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients. The Company is currently enrolling patients in its ongoing, BARDA-funded RedeS clinical trial, the second pivotal U.S. Phase 3


clinical trial in patient populations requiring RBC transfusion for acute and chronic anemia. Results from both trials are expected to be part of a planned modular PMA submission to the FDA, with the planned final PMA module expected to be submitted upon the anticipated completion of the RedeS trial.

“ReCePI investigators will be presenting a number of abstracts with study data at the Annual AABB meeting next week in Houston, including a plenary presentation,” said Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer. “We have recently begun enrolling at two additional RedeS study sites, including the Turkey site, but we are still assessing the potential impact to the anticipated timing of study completion and modular PMA submission, since these new sites began enrollment later than previously anticipated.”

The new BARDA contract will be funded in whole or in part with federal funds from the Department of Health and Human Services’ Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract No. 75A50124C00046.

Europe – CE Mark review update

For Cerus’ MDR application in Europe, Cerus’ Notified Body, TÜV-SÜD, reviewed the modules for clinical, non-clinical, manufacturing and quality and found them to be satisfactory. However, the Competent Authority, CBG-MEB, reviewed the active pharmaceutical ingredient module and concluded that the data included in the module were insufficient to support the proposed classification of the impurity profile of the final product, necessitating TÜV-SÜD’s closure of Cerus’ MDR application without an approval. The Company, in collaboration with TÜV-SÜD, is assessing strategies for a potential enhanced new regulatory submission and the associated timeline.

“We continue to believe strongly in the need for pathogen inactivated RBCs and the regulatory dossier we filed in Europe. In addition to how we address the new questions CBG has raised, we want to take this opportunity to be thoughtful about leveraging the additional data that we have accumulated since our original CE Mark submission,” said Carol Moore, Cerus’ senior vice president. “For example, we believe the positive results from our U.S. Phase 3 ReCePI trial substantially expand the data available to evaluate the clinical safety and efficacy of INTERCEPT RBCs. We will be assessing how these data could allow us to propose a broader clinical indication in a potential new CE Mark submission in consultation with TÜV.”

Webcast

The Company will host a webcast later today at 5:00 P.M. EDT, during which management will provide an update on the INTERCEPT red blood cell program. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.



2


A replay will be available on Cerus’ website approximately three hours after the call through October 30, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

CERS
Cerus Corp
1.4788
-0.3262 (-18.07%)
Volume: 2,395,912
Day Range: 1.375 - 1.64
Bid: 1.47
Ask: 1.48
Last Trade Time: 10:34:39 AM EDT
Total Trades: 6,116

with new contract do we need europe ?????

with new contract should be higher ,

https://www.otcmarkets.com/filing/html?id=17898975&guid=RbL-kamhH0mnJth

how you like contract unknown ????? anyone ?????

This stock is on the move ...
Do NOT miss it before it takes off!!
Nearly 70% of of all analyst agree !
At 2 bucks your nuts 🥜 not to pick up some shares now !

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

CERS new 52 week low

$CERS Book Value Per Share (mrq) ONLY $0.65

Looks like CP using Intercept plasma will push the SP well over $7 and just could go over $20 if key metrics indicate a possible buy out. Since the closest competition Mirasol is now a non-starter with the FDA last week, CERS occupies a monopoly position. That is not to mention RBS approval in the next few years as well as the now released info that American Red Cross will not guarantee requested shipment fulfillment if Intercept is not stipulated. CERS now owns the market along with locked in distributors throughout the world. No brainer investment for the whole next decade. Even buying at $20 SP will be a 10 bagger in5 yeas or less. Probably less. Very long here.

Looking for entry, awesome growth and balance sheet, could be a good Covid play jmo

* * $CERS Video Chart 02-13-2020 * *

Link to Video - click here to watch the technical chart video

* * $CERS Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

* * $CERS Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

CERS been in this play for 2 months now...time to make some noise!!!

Longer term technical promise. http://stockcharts.com/public/1164099

From Berkshire Hathaway's - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Recent developments and highlights include:

*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a

17% to 22% increase over 2017 reported product revenue.

*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.

IMO it is up from here and a buy at $5.

NAVY Department worth more than today's 4 cent CERS SP rise. Description: Department of the Navy

Bureau of Medicine and Surgery

U.S. Naval Hospital Guam

US Naval Hospital Guam intends to award a sole-source drop-shipment contract under the authority of FAR 13, due to the only source available to meet the Government's needs, to Cerus Corporation, 2550 Stanwell Drive, Concord, CA 94520. Reference NAICS Code 325412. The following products will be procured: 0001. INTERCEPT Platelet Small Volume Processing Set, P/N INT2110B. Quantity: 8 Cases (2 cases to be delivered on March 2018, May 2018, July 2018, and Sep 2018). 0002. INTERCEPT Platelet Processing Set with Dual Storage Containers, P/N INT2510B. Quantity: 5 Cases (2 cases to be delivered on March 2018, 1 case to be delivered on May 2018, July 2018, and Sep 2018. This notice of intent is not a request for competitive proposals.

FULL INFO https://www.fbo.gov/spg/DON/BUMED/N68096/N6809618Q0008/listing.html

Time for a big thumbs up on that start!!

Shorts attacked it well today

Good new out yesterday after regarding CERS trials. Stock is steadily moving UP!!!

Yesterday, today and tomorrow!

* * $CERS Video Chart 11-03-17 * *

Link to Video - click here to watch the technical chart video

Big news!!!

Is this today's bio play?

What a joke!!!!!!!!!!!!!!!!!!!!!!! Played the Zika! Pump and now Dump!!!

* * $CERS Video Chart 08-08-17 * *

Link to Video - click here to watch the technical chart video